Elevance Health (NYSE:ELV – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported $7.45 EPS for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24, Briefing.com reports. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. During the same quarter last year, the business posted $8.84 EPS. The firm’s quarterly revenue was up .8% compared to the same quarter last year.
Here are the key takeaways from Elevance Health’s conference call:
- Elevance Health reported Q2 adjusted EPS of $7.45, ahead of expectations, and raised full-year 2026 guidance to at least $27. Management also reiterated confidence in returning to at least 12% adjusted EPS growth in 2027 off the 2026 baseline.
- Medicaid remains the weakest area, with full-year operating margin guidance held at approximately -1.75%. The company said elevated utilization is persisting in behavioral health, specialty pharmacy, outpatient surgery, and ER use, though it expects the second half to improve modestly.
- Medicare Advantage outperformed in the quarter, helped by portfolio repositioning, better claims experience, and care management actions. Management said the business is on track for an operating margin of at least 2% in 2026.
- The company is making targeted one-time investments in 2H 2026 using a net below-the-line benefit, aimed at medical cost management, member engagement, provider connectivity, and Carelon capabilities. Management stressed these costs are non-recurring and should not repeat in 2027.
- Carelon and commercial performance are progressing as planned, with Carelon’s value-based and behavioral health offerings contributing more meaningfully over time and commercial demand remaining strong. Elevance also said its ACA business is tracking to plan and expects to end 2026 with at least 1 million ACA members.
Elevance Health Stock Performance
Shares of NYSE:ELV opened at $389.85 on Thursday. The firm has a market capitalization of $84.66 billion, a PE ratio of 16.58, a P/E/G ratio of 2.42 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The business has a 50-day moving average of $399.67 and a two-hundred day moving average of $355.07. Elevance Health has a 12 month low of $273.71 and a 12 month high of $436.24.
Elevance Health Announces Dividend
Key Stories Impacting Elevance Health
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Elevance Health beat Q2 expectations on both earnings and revenue, with EPS of $7.45 versus estimates around $6.18-$6.21 and revenue of $49.83 billion topping forecasts. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, signaling management is more confident in profit trends and medical cost control for the rest of the year. Elevance raises annual profit forecast on better medical cost management
- Positive Sentiment: Analyst sentiment remained supportive, with Truist lifting its price target to $475 and reiterating a buy rating after the earnings update. Elevance Health (NYSE:ELV) Price Target Raised to $475.00 at Truist Financial
- Neutral Sentiment: Recent earnings-call coverage highlighted growth opportunities in CarelonRx and operating improvements, but also noted that the company is navigating strain from higher costs and softer membership trends. Elevance Health earnings call: growth levers amid strain
- Negative Sentiment: Despite the earnings beat, some reports said the shares slipped on margin pressure and the company is leaving more Medicaid markets, which could weigh on investor sentiment around future growth. Elevance Health (ELV) Beats Q2 And Raises Outlook While Leaving More Medicaid Markets
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Jefferies Financial Group decreased their price target on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Raymond James Financial set a $450.00 price objective on shares of Elevance Health in a research report on Tuesday, July 7th. Wells Fargo & Company upped their price objective on shares of Elevance Health from $391.00 to $492.00 and gave the company an “overweight” rating in a research note on Monday. Truist Financial raised their target price on shares of Elevance Health from $450.00 to $475.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft raised shares of Elevance Health from a “hold” rating to a “buy” rating and lifted their target price for the stock from $363.00 to $498.00 in a research note on Wednesday, May 20th. Fifteen research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $435.05.
Get Our Latest Analysis on ELV
Insider Buying and Selling at Elevance Health
In other news, Director Robert L. Dixon, Jr. sold 151 shares of Elevance Health stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director directly owned 10,734 shares of the company’s stock, valued at $4,312,599.18. The trade was a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.34% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Kemnay Advisory Services Inc. acquired a new stake in shares of Elevance Health in the fourth quarter worth $31,000. J.Safra Asset Management Corp acquired a new position in shares of Elevance Health during the 4th quarter valued at $32,000. Jessup Wealth Management Inc purchased a new stake in Elevance Health during the 4th quarter worth $45,000. Garton & Associates Financial Advisors LLC purchased a new stake in Elevance Health during the 4th quarter worth $50,000. Finally, Rossby Financial LCC increased its holdings in Elevance Health by 85.7% in the 4th quarter. Rossby Financial LCC now owns 156 shares of the company’s stock valued at $55,000 after purchasing an additional 72 shares in the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.
Elevance Health Company Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
- Five stocks we like better than Elevance Health
- Which Storage Stock Is Best Positioned to Win the AI Memory War?
- Tesla’s Delivery Surprise Was Big—Earnings Need to Be Bigger
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
